Rona L Levy1, Miranda A L van Tilburg, Shelby L Langer, Joan M Romano, Lynn S Walker, Lloyd A Mancl, Tasha B Murphy, Robyn L Claar, Shara I Feld, Dennis L Christie, Bisher Abdullah, Melissa M DuPen, Kimberly S Swanson, Melissa D Baker, Susan A Stoner, William E Whitehead. 1. *School of Social Work, University of Washington, Seattle, Washington; †Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina; ‡Department of Psychiatry & Behavioral Sciences, University of Washington, Seattle, Washington; §Department of Pediatrics, Vanderbilt University, Nashville, Tennessee; ‖Department of Oral Health Sciences, University of Washington, Seattle, Washington; ¶School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin; **Department of Gastroenterology, Seattle Children's Hospital, Seattle, Washington; ††Prime Health Clinic, Federal Way, Washington; ‡‡St. Charles Health System, Bend, Oregon; §§HealthPoint, Bothell, Washington; and ‖‖Alcohol and Drug Abuse Institute, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: Studies testing the efficacy of behavioral interventions to modify psychosocial sequelae of inflammatory bowel disease in children are limited. This report presents outcomes through a 6-month follow-up from a large randomized controlled trial testing the efficacy of a cognitive behavioral intervention for children with inflammatory bowel disease and their parents. METHODS:One hundred eighty-five children aged 8 to 17 years with a diagnosis of Crohn's disease or ulcerative colitis and their parents were randomized to one of two 3-session conditions: (1) a social learning and cognitive behavioral therapy condition or (2) an education support condition designed to control for time and attention. RESULTS: There was a significant overall treatment effect for school absences due to Crohn's disease or ulcerative colitis (P < 0.05) at 6 months after treatment. There was also a significant overall effect after treatment for child-reported quality of life (P < 0.05), parent-reported increases in adaptive child coping (P < 0.001), and reductions in parents' maladaptive responses to children's symptoms (P < 0.05). Finally, exploratory analyses indicated that for children with a higher level of flares (2 or more) prebaseline, those in social learning and cognitive behavioral therapy condition experienced a greater reduction in flares after treatment. CONCLUSIONS: This trial suggests that a brief cognitive behavioral intervention for children with inflammatory bowel disease and their parents can result in improved child functioning and quality of life, and for some children may decrease disease activity.
RCT Entities:
BACKGROUND: Studies testing the efficacy of behavioral interventions to modify psychosocial sequelae of inflammatory bowel disease in children are limited. This report presents outcomes through a 6-month follow-up from a large randomized controlled trial testing the efficacy of a cognitive behavioral intervention for children with inflammatory bowel disease and their parents. METHODS: One hundred eighty-five children aged 8 to 17 years with a diagnosis of Crohn's disease or ulcerative colitis and their parents were randomized to one of two 3-session conditions: (1) a social learning and cognitive behavioral therapy condition or (2) an education support condition designed to control for time and attention. RESULTS: There was a significant overall treatment effect for school absences due to Crohn's disease or ulcerative colitis (P < 0.05) at 6 months after treatment. There was also a significant overall effect after treatment for child-reported quality of life (P < 0.05), parent-reported increases in adaptive child coping (P < 0.001), and reductions in parents' maladaptive responses to children's symptoms (P < 0.05). Finally, exploratory analyses indicated that for children with a higher level of flares (2 or more) prebaseline, those in social learning and cognitive behavioral therapy condition experienced a greater reduction in flares after treatment. CONCLUSIONS: This trial suggests that a brief cognitive behavioral intervention for children with inflammatory bowel disease and their parents can result in improved child functioning and quality of life, and for some children may decrease disease activity.
Authors: Eva Szigethy; Simona I Bujoreanu; Ada O Youk; John Weisz; David Benhayon; Diane Fairclough; Peter Ducharme; Joseph Gonzalez-Heydrich; David Keljo; Arvind Srinath; Athos Bousvaros; Margaret Kirshner; Melissa Newara; David Kupfer; David R DeMaso Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-05-10 Impact factor: 8.829
Authors: Rona L Levy; Shelby L Langer; Lynn S Walker; Joan M Romano; Dennis L Christie; Nader Youssef; Melissa M DuPen; Sheri A Ballard; Jennifer Labus; Ericka Welsh; Lauren D Feld; William E Whitehead Journal: JAMA Pediatr Date: 2013-02 Impact factor: 16.193
Authors: Laura E Targownik; Kathryn A Sexton; Matthew T Bernstein; Brooke Beatie; Michael Sargent; John R Walker; Lesley A Graff Journal: Am J Gastroenterol Date: 2015-06-16 Impact factor: 10.864
Authors: Laura M Mackner; Rachel Neff Greenley; Eva Szigethy; Michele Herzer; Kate Deer; Kevin A Hommel Journal: J Pediatr Gastroenterol Nutr Date: 2013-04 Impact factor: 2.839
Authors: Luuk Stapersma; Gertrude van den Brink; Jan van der Ende; Eva M Szigethy; Ruud Beukers; Thea A Korpershoek; Sabine D M Theuns-Valks; Manon H J Hillegers; Johanna C Escher; Elisabeth M W J Utens Journal: J Pediatr Psychol Date: 2018-10-01
Authors: Bonney Reed-Knight; Miranda A L van Tilburg; Rona L Levy; Shelby L Langer; Joan M Romano; Tasha B Murphy; Melissa M DuPen; Andrew D Feld Journal: J Pediatr Psychol Date: 2018-01-01
Authors: Miranda A L van Tilburg; Robyn Lewis Claar; Joan M Romano; Shelby L Langer; Douglas A Drossman; William E Whitehead; Bisher Abdullah; Rona L Levy Journal: J Pediatr Date: 2017-02-24 Impact factor: 4.406
Authors: Shelby L Langer; Joan Romano; Jonathon D Brown; Heather Nielson; Bobby Ou; Christina Rauch; Lirra Zullo; Rona L Levy Journal: Pain Date: 2017-09 Impact factor: 7.926